"Antibodies, Bispecific" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
| Descriptor ID |
D018033
|
| MeSH Number(s) |
D12.776.124.486.485.114.125 D12.776.124.790.651.114.134 D12.776.377.715.548.114.134
|
| Concept/Terms |
Antibodies, Bispecific- Antibodies, Bispecific
- Bispecific Antibodies
- Bifunctional Antibodies
- Antibodies, Bifunctional
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Bispecific".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Bispecific".
This graph shows the total number of publications written about "Antibodies, Bispecific" by people in this website by year, and whether "Antibodies, Bispecific" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 1 | 3 |
| 2019 | 3 | 0 | 3 |
| 2020 | 1 | 1 | 2 |
| 2021 | 5 | 0 | 5 |
| 2022 | 1 | 0 | 1 |
| 2023 | 4 | 0 | 4 |
| 2024 | 3 | 2 | 5 |
| 2025 | 7 | 4 | 11 |
| 2026 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Bispecific" by people in Profiles.
-
Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e517460.
-
Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study. J Clin Oncol. 2026 Aug 20; 44(24):2271-2277.
-
Blinatumomab Utilization in Pediatric B-Cell Acute Lymphoblastic Leukemia: Experience From the Mountain West. Pediatr Blood Cancer. 2026 Jul; 73(7):e70383.
-
Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL. Blood. 2026 04 23; 147(17):2011-2017.
-
Targeting BCMA in Plasmablastic Lymphoma With Teclistamab: A Case Study of Three Patients. J Natl Compr Canc Netw. 2026 Feb 19; 24(3):128-131.
-
Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight. Hematology Am Soc Hematol Educ Program. 2025 12 05; 2025(1):334-341.
-
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent. Adv Ther. 2026 01; 43(1):333-355.
-
Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study. Oral Oncol. 2025 Dec; 171:107791.
-
Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models. J Immunother Cancer. 2025 Oct 28; 13(10).
-
Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results. J Clin Oncol. 2025 11 10; 43(32):3526-3535.